Effects of switching from anastrozole to letrozole, due to reimbursement policy, on the outcome of breast cancer therapy

BACKGROUND: Endocrine therapy is one of the standard treatments for estrogen-receptor-positive breast cancer patients. Letrozole is the only aromatase inhibitor (AI) included in Thailand’s essential drug list since the change of reimbursement policy in 2008, when patients had to change their AIs (ot...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Aphinives, Potchavit, Vachirodom, Damnern, Thanapaisal, Chaiyut, Rangsrikajee, Dhanes, Somintara, Ongart
Formato: Artigo
Idioma:Inglês
Publicado: Dove Medical Press 2014
Assuntos:
Original Research
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4154879/
https://ncbi.nlm.nih.gov/pubmed/25249759
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/BCTT.S67553
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares